z-logo
Premium
Influence of adjuvants on murine immune responses against the C‐terminal 19 kDa fragment of Plasmodium vivax merozoite surface protein‐1 (MSP‐1)
Author(s) -
Yang Chunfu,
Collins William E.,
Xiao Lihua,
Patterson Pamela S.,
Reed Robb C.,
Hunter Robert L.,
Kaslow David C.,
Lal Altaf A.
Publication year - 1996
Publication title -
parasite immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.795
H-Index - 75
eISSN - 1365-3024
pISSN - 0141-9838
DOI - 10.1046/j.1365-3024.1996.d01-32.x
Subject(s) - biology , merozoite surface protein , immune system , plasmodium vivax , surface protein , immunology , virology , malaria , plasmodium falciparum , malaria vaccine
The immunogenicity of a yeast‐expressed 19 kDa fragment of P vivax MSP‐1 in the presence of different adjuvant formulations was evaluated. ICR mice were immunized with the 19 kDa antigen, using Freund's, alum, and block copolymer P1005 in water‐in‐oil (W/O) or oil‐in‐water (O/W) emulsions with or without detoxified lipopolysaccharide (RaLPS) as adjuvants. Five weeks following immunization with the antigen, mice were boosted with asexual blood‐stage antigens. Three weeks after the last immunization with the 19 kDa antigen, mice from the Freund's group and most groups that received P1005 as adjuvant had higher total IgG titres than those that received alum as adjuvant or antigen alone. Antibody responses after the antigen immunization were predominantly of the IgG1 isotype, but mice in the Freund's and P1005 (W/O or O/W emulsion with or without RaLPS) groups also had high titres of IgG2a and IgG2b. Antibody titres against merozoites increased in all groups after the parasite antigen boost. IgG2a levels in the group that received antigen in P1005 plus RaLPS in the W/O emulsion were higher than those receiving Freund's, alum or the other copolymer adjuvants. The high IgG2a titres in this group were associated with reduced IL‐10 production.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here